Table 1.
Association of plasma fibrinogen with clinicopathologic factors in patients with stage I‐II gastric cancer
| Factors | N | PFC <4 g/L (PFC0 stage) | PFC≧4 g/L (PFC1 stage) | P | PFC (g/L) (median ± IQR) | P |
|---|---|---|---|---|---|---|
| Gender | ||||||
| Male | 570 (71.9%) | 410 (71.9%) | 160 (28.1%) | 0.219* | 3.41 ± 1.26 | 0.615† |
| Female | 223 (28.1%) | 170 (76.2%) | 53 (23.8%) | 3.43 ± 1.08 | ||
| Age | ||||||
| <60 y | 449 (56.6%) | 358 (79.1%) | 91 (20.3%) | <0.001* | 3.28 ± 1.03 | <0.001† |
| ≧60 y | 344 (43.4%) | 222 (64.5%) | 122 (35.5%) | 3.61 ± 1.25 | ||
| Tumor size | ||||||
| <5 cm | 571 (72%) | 445 (77.9%) | 126 (22.1%) | 0.000* | 3.30 ± 1.03 | <0.001† |
| ≧5 cm | 222 (28.0%) | 135 (60.8%) | 87 (39.2%) | 3.78 ± 1.25 | ||
| Tumor location | ||||||
| Upper | 76 (9.6%) | 55 (72.4%) | 21 (27.6%) | 0.873* | 3.40 ± 1.15 | 0.871† |
| Middle‐Lower | 717 (90.4%) | 525 (73.2%) | 192 (26.8%) | 3.43 ± 1.24 | ||
| Borrmann type | ||||||
| Borrmann 1 | 30 (6.0%) | 23 (76.7%) | 11 (23.3%) | 0.329* | 3.51 ± 1.16 | 0.386† |
| Borrmann 2 | 61 (12.3%) | 45 (73.8%) | 16 (26.2%) | 3.35 ± 1.00 | ||
| Borrmann 3 | 382 (76.9%) | 248 (64.9%) | 134 (35.1%) | 3.61 ± 1.22 | ||
| Borrmann 4 | 24 (4.8%) | 17 (70.8%) | 7 (29.4%) | 3.59 ± 1.48 | ||
| Differentiation | ||||||
| High | 112 (12.1%) | 79 (70.5%) | 33 (29.5%) | 0.138* | 3.54 ± 1.31 | 0.026† |
| Moderate | 263 (33.2%) | 184 (74.0%) | 79 (30.0%) | 3.54 ± 1.28 | ||
| Poor | 233 (29.4%) | 170 (73.0%) | 63 (27.0%) | 3.36 ± 1.30 | ||
| Non | 185 (23.3%) | 147 (79.5%) | 38 (20.5%) | 3.34 ± 0.99 | ||
| Lymphovascular invasion | ||||||
| Negative | 705 (88.9%) | 520 (73.8%) | 185 (26.2%) | 0.266* | 3.41 ± 1.09 | 0.397† |
| Positive | 88 (11.1%) | 60 (68.2%) | 28 (31.8%) | 3.51 ± 1.33 | ||
| T stage | ||||||
| T1 | 296 (37.3%) | 247 (83.4%) | 49 (16.6%) | 0.000* | 3.16 ± 0.97 | <0.001† |
| T2 | 202 (25.5%) | 146 (72.3%) | 56 (27.7%) | 3.38 ± 1.16 | ||
| T3 | 204 (25.7%) | 125 (21.3%) | 79 (38.7%) | 3.69 ± 1.29 | ||
| T4a | 91 (11.5%) | 62 (68.1%) | 29 (31.9%) | 3.70 ± 1.18 | ||
| pN stage | ||||||
| N0 | 569 (71.8%) | 424 (74.5%) | 145 (25.5%) | 0.163* | 3.39 ± 1.15 | 0.040† |
| N(1‐3a) | 224 (28.2%) | 156 (69.6%) | 68 (30.4%) | 3.50 ± 1.25 | ||
| AJCC stage | ||||||
| IA | 261 (32.9%) | 219 (83.9%) | 42 (16.1%) | <0.001* | 3.17 ± 0.98 | <0.001† |
| IB | 135 (17.0%) | 97 (71.9%) | 38 (28.1%) | 3.33 ± 1.19 | ||
| IIA | 156 (19.7%) | 105 (67.3%) | 51 (32.7%) | 3.58 ± 1.31 | ||
| IIB | 241 (30.4%) | 159 (66.0%) | 82 (34.0%) | 3.61 ± 1.18 | ||
| Pretreatment Anemia | ||||||
| Anemia | 175 (22.1%) | 104 (59.4) | 71 (40.6%) | <0.001* | 3.75 ± 1.65 | <0.001† |
| Normal | 618 (77.9%) | 476 (77.0%) | 142 (23.0%) | 3.37 ± 1.06 | ||
| Blood platelet | ||||||
| <300/L | 660 (83.2%) | 514 (77.9%) | 146 (22.1%) | <0.001* | 3.34 ± 1.06 | <0.001† |
| ≧300 g/L | 133 (16.8%) | 66 (49.6%) | 67 (50.4%) | 4.00 ± 1.40 |
IQR, interquartile range; PFC, plasma fibrinogen concentration; PFC0, plasma fibrinogen concentration <4 g/L; PFC1, plasma fibrinogen concentration ≧4 g/L.
*
Chi‐squared test.
†
Kruskal‐Wallis or Mann‐Whitney U test.